Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CVRX 
CVRx Inc (CVRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: CVRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.83
1 Year Target Price $10.83
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.73% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 256.03M USD | Price to earnings Ratio - | 1Y Target Price 10.83 |
Price to earnings Ratio - | 1Y Target Price 10.83 | ||
Volume (30-day avg) 7 | Beta 1.25 | 52 Weeks Range 4.30 - 18.55 | Updated Date 11/6/2025 |
52 Weeks Range 4.30 - 18.55 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When After Market | Estimate -0.5 | Actual -0.49 |
Profitability
Profit Margin -95.61% | Operating Margin (TTM) -105.79% |
Management Effectiveness
Return on Assets (TTM) -29.63% | Return on Equity (TTM) -92.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 160971080 | Price to Sales(TTM) 4.68 |
Enterprise Value 160971080 | Price to Sales(TTM) 4.68 | ||
Enterprise Value to Revenue 2.95 | Enterprise Value to EBITDA -1.31 | Shares Outstanding 26072599 | Shares Floating 17964142 |
Shares Outstanding 26072599 | Shares Floating 17964142 | ||
Percent Insiders 4.31 | Percent Institutions 67.56 |
Upturn AI SWOT
CVRx Inc
Company Overview
History and Background
CVRx, Inc. is a medical device company focused on developing, manufacturing, and marketing innovative neuromodulation solutions for patients with cardiovascular diseases. It was founded in 2000 and is headquartered in Minneapolis, Minnesota. The company has focused on the development and commercialization of its Barostim System for heart failure and hypertension.
Core Business Areas
- Neuromodulation Therapies: CVRx focuses on developing and commercializing neuromodulation therapies for cardiovascular diseases. Their flagship product, the Barostim System, is designed to stimulate baroreceptors in the carotid artery to reduce sympathetic activity and improve cardiovascular function.
Leadership and Structure
CVRx is led by Nadim Yared as President and Chief Executive Officer. The company has a typical organizational structure for a medical device company, with departments for research and development, manufacturing, sales and marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Barostim System: The Barostim System is CVRx's primary product. It is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery. This stimulation modulates the autonomic nervous system, leading to reduced sympathetic activity and improved cardiovascular function in patients with heart failure and hypertension. Market share data is difficult to determine exactly as CVRx has this unique approach. Key competitors include companies offering other heart failure management devices like Medtronic (MDT) and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The neuromodulation market is growing, driven by the increasing prevalence of chronic diseases and the desire for less invasive treatment options. The cardiovascular device market is highly competitive and regulated.
Positioning
CVRx is positioned as a leader in neuromodulation therapies for cardiovascular disease, specifically heart failure and hypertension. The Barostim System offers a novel approach to managing these conditions by targeting the autonomic nervous system.
Total Addressable Market (TAM)
The estimated TAM for neuromodulation therapies in cardiovascular disease is significant, potentially reaching billions of dollars globally. CVRx is positioned to capture a share of this market with its Barostim System, particularly among patients who are not adequately managed with traditional therapies.
Upturn SWOT Analysis
Strengths
- Proprietary technology (Barostim System)
- Clinical evidence supporting efficacy
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited product portfolio
- Reliance on Barostim System
- Requires specialized training for implantation
- Negative cash flow
Opportunities
- Expansion into new indications (e.g., resistant hypertension)
- Geographic expansion (e.g., Europe, Asia)
- Partnerships with other medical device companies
- Further clinical studies to strengthen evidence base
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- BSX
- SYK
Competitive Landscape
CVRx has a unique technology, but its smaller size and limited resources make it challenging to compete with larger, established medical device companies like Medtronic and Boston Scientific. Their competitors are much more established and have a wide range of heart failure devices which command the market share
Growth Trajectory and Initiatives
Historical Growth: CVRx has experienced revenue growth in recent years as the Barostim System gains wider acceptance.
Future Projections: Analyst estimates project continued revenue growth for CVRx, driven by increased adoption of the Barostim System and potential expansion into new indications. Profitability is expected to improve in the coming years.
Recent Initiatives: CVRx has focused on expanding its sales force, conducting clinical studies, and securing reimbursement for the Barostim System.
Summary
CVRx is an innovative medical device company with a promising technology for treating heart failure and hypertension. The company has achieved revenue growth but faces challenges related to profitability, competition, and reimbursement. Its unique approach positions it well, but commercial success depends on the increased adoption of the Barostim System and future funding to continue its operations and growth. Investors should monitor the company's progress in securing reimbursement and achieving profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CVRx Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2021-06-30 | President, CEO & Director Mr. Kevin Hykes | ||
Sector Healthcare | Industry Medical Devices | Full time employees 206 | Website https://www.cvrx.com |
Full time employees 206 | Website https://www.cvrx.com | ||
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.